Imprimis Pharmaceuticals acquires the intellectual property rights for ophthalmic compound from Novel Drug Solutions

|About: Imprimis Pharmaceuticals, Inc. (IMMY)|By:, SA News Editor

Imprimis Pharmaceuticals (IMMY -4.7%) acquires the intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents from Novel Drug Solutions.

The target compound, referred to as IPI-140, is based on a combination of moxifloxacin and triamcinolone.

IMMY says it believes the formulation has the potential to "impact the fast-growing $5B global cataract surgery drug market."

Additionally, the deal gives IMMY preemptive rights to other Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.